title: Therapeutic management of metastatic medullary thyroid carcinoma: role of new tyrosine kinase inhibitors.
authors.forename: Antonia
authors.initials: A
authors.lastname: García-Martín
authors.forename: Pablo José
authors.initials: PJ
authors.lastname: López-Ibarra Lozano
authors.forename: Eva María
authors.initials: EM
authors.lastname: Triviño-Ibáñez
authors.forename: Fernando
authors.initials: F
authors.lastname: Escobar-Jiménez
mesh_terms: D018278:Carcinoma, Neuroendocrine; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D000077157:Sorafenib; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000473:pathology*
chemical_list: D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D009536:Niacinamide; D000077157:Sorafenib; D011505:Protein-Tyrosine Kinases